On Tuesday, The Washington Examiner posted an article about Monkeypox. The article provides a brief summary of the things the public needs to know.

Here are some excerpts:

In total, 92 cases of monkeypox have been confirmed so far, with another 28 suspected cases, according to the World Health Organization. Most of the cases in the U.K. and Europe have been in young men with no history of travel to Africa and who were gay, bisexual, or had sex with men.

…All of the cases that have been confirmed through a PCR test were infected by the strain native to West Africa, but only one case has a direct tie to the region. The first to be confirmed in the U.K. was a person who had traveled from the U.K. to Nigeria and back. The person was immediately isolated upon return, and “the risk of onward transmission related to this case in the United Kingdom is minimal,” the WHO said. But that still leaves open the question of where the dozens of other cases came from.

A leading adviser to the WHO, Dr. David Heymann, told the Associated Press that sexual transmission at two raves in Belgium and Spain appear to have been major catalysts for the spread of the virus in Europe.

…There is not currently a vaccine made specifically to prevent monkeypox infection, but smallpox vaccines have proven to be at least 85% effective in preventing monkeypox. Experts also believe that administering a smallpox vaccine after a monkeypox exposure may help prevent the disease or make it less severe.

The article concludes:

Infectious disease experts said this outbreak is very different from COVID-19, which caught the U.S. public health infrastructure off guard. Unlike symptoms of COVID-19 infection, symptoms of monkeypox are visual and cases are easier to trace. Monkeypox is also far less transmissible than COVID-19. And unlike COVID-19, monkeypox is not an airborne pathogen.

“Contact tracing COVID-19 is a nightmare, and I don’t want to say it’s a piece of cake, but it’s a much more straightforward proposition [to trace monkeypox],” said Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine and co-director of the Texas Children’s Hospital Center for Vaccine Development.

The Food and Drug Administration has also approved several antiviral medications to treat smallpox and diseases like it.

“That’s why I’m pretty optimistic that we’ll be able to contain it because the overall level of transmissibility is low, the incubation period is longer, and in about two weeks, the characteristic rash makes contact tracing easier, and we already have vaccines and antiviral drugs ready to go. … [COVID-19 is] really just the opposite of monkeypox,” Hotez told the Washington Examiner.

At least there is some good news.